NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT05054725 2026-01-06Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesRevolution Medicines, Inc.Phase 2 Completed47 enrolled 17 charts
NCT03767517 2025-05-23A Culturally-Based Palliative Care Tele-consult Program for Rural Southern EldersUniversity of Alabama at BirminghamPhase NA Completed209 enrolled 16 charts
NCT04925986 2025-04-17Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCYale UniversityPhase 2 Terminated9 enrolled 15 charts
NCT04512430 2025-04-02Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsFundación GECPPhase 2 Terminated4 enrolled 9 charts